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Abstract
Background
The chromosomal region 6q23 has been found to be associated with multiple sclerosis (MS)
predisposition through genome wide association studies (GWAS). There are four indepen-
dent single nucleotide polymorphisms (SNPs) associated with MS in this region, which
spans around 2.5 Mb. Most GWAS variants associated with complex traits, including these
four MS associated SNPs, are non-coding and their function is currently unknown. However,
GWAS variants have been found to be enriched in enhancers and there is evidence that
they may be involved in transcriptional regulation of their distant target genes through long
range chromatin looping.
Aim
The aim of this work is to identify causal disease genes in the 6q23 locus by studying long
range chromatin interactions, using the recently developed Capture Hi-C method in human
T and B-cell lines. Interactions involving four independent associations unique to MS,
tagged by rs11154801, rs17066096, rs7769192 and rs67297943 were analysed using Cap-
ture Hi-C Analysis of Genomic Organisation (CHiCAGO).
Results
We found that the pattern of chromatin looping interactions in the MS 6q23 associated
region is complex. Interactions cluster in two regions, the first involving the rs11154801
region and a second containing the rs17066096, rs7769192 and rs67297943 SNPs. Firstly,
SNPs located within the AHI1 gene, tagged by rs11154801, are correlated with expression
of AHI1 and interact with its promoter. These SNPs also interact with other potential
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candidate genes such as SGK1 and BCLAF1. Secondly, the rs17066096, rs7769192 and
rs67297943 SNPs interact with each other and with immune-related genes such as IL20RA,
IL22RA2, IFNGR1 and TNFAIP3. Finally, the above-mentioned regions interact with each
other and therefore, may co-regulate these target genes.
Conclusion
These results suggest that the four 6q23 variants, independently associated with MS, are
involved in the regulation of several genes, including immune genes. These findings could
help understand mechanisms of disease and suggest potential novel therapeutic targets.
Introduction
Genome wide association studies (GWAS) have been pivotal in identifying genetic associa-
tions with single nucleotide polymorphisms (SNPs) in many complex diseases, including mul-
tiple sclerosis (MS) [1–4]. MS is an inflammatory demyelinating disease of the central nervous
system (CNS) and is a common cause of chronic neurological disability, showing moderate
heritability (λs ~6.3) [5]. Similar to many autoimmune diseases, the major histocompatibility
complex (MHC) represents the largest single genetic risk factor for MS, with multiple non-
HLA loci, discovered in large international GWAS, contributing smaller individual effects to
disease susceptibility. Due to the extensive overlap of genetic loci between multiple autoim-
mune diseases, the International Multiple Sclerosis Genetics Consortium (IMSGC) conducted
a large study using the Illumina Immunochip genotyping array, identifying 48 new and vali-
dating 49 previously discovered non-MHC susceptibility variants for MS [6]. Among these
variants, four mapped to the 6q23 region, which is also associated with other autoimmune dis-
eases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), celiac disease
(CeD), type 1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis (Ps) and psoriatic
arthritis (PsA), and containing several candidate genes, such as TNFAIP3, AHI1 and IL22RA2
[7–13].
The 6q23 locus, like many other GWAS loci, shows extensive overlap with many other auto-
immune diseases and demonstrates a complex pattern of different associations attributable to
different diseases. This sharing of associated loci led to the Immunochip array which contains
three regions densely mapped and capturing four independent associations with MS (Table 1
and Fig 1) in the 6q23 region. The first, tagged by rs11154801, is located within an intron of
the AHI1 gene required for both cerebellar and cortical development. The second region,
tagged by rs17066096, is an intergenic region 87kb 5’ of IL20RA and 12kb 3’ of IL22RA2. The
third region covers 430kb, encompassing a PTPN11 pseudogene (RP11-95M15.2),TNFAIP3
and several lncRNAs and contains two independent associations (rs7769192 & rs67297943).
Interestingly, while other SNP associations are shared between autoimmune diseases, the MS
associated SNPs are unique to MS alone (S1 Data). As such, these MS associated SNPs could
offer an insight into the mechanisms affecting MS at this locus.
However, due to the design of GWAS, these lead genetic associations do not necessarily
represent the causal variant but instead a number of variants in strong linkage disequilibrium
with them. In addition, associated SNPs have generally been annotated to the closest, most bio-
logically plausible gene. Evidence suggests that GWAS discovered SNPs in general, including
these associations within 6q23, are enriched in cell-type specific enhancer regions [14,15]
which can regulate gene expression. Additionally, an individual’s genotype can influence this
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expression (expression quantitative trait loci (eQTL)), potentially leading to disease. It has
been shown that enhancers can regulate genes located some distance away through long-range
chromatin interactions [16]. Therefore, confidently assigning causal SNPs, genes and cell types
to these and other GWAS signals remains a major challenge. Potential long-range interactions
have previously been prohibitive to investigate as methods, such as 3C and Hi-C, required
interacting regions to be considered a priori or, lacked throughput and resolution. Capture Hi-
C was developed to overcome these limitations by enriching a Hi-C library using RNA baits
designed to specific restriction fragments. This approach reduces library complexity, increases
power and subsequently allows the identification of statistically significant chromatin interac-
tions at a restriction fragment resolution (~4kb). As part of a large study investigating the
interactions with associated regions in four autoimmune diseases [17], several sites within the
6q23 region were targeted, including associated regions and promoters of nearby genes
(Table 1 and Fig 1). Our Capture Hi-C data represents a unique opportunity to explore this
region for MS and offer an insight into the mechanisms specifically affecting MS at this locus
and how they compare with other autoimmune diseases. The aim of this study was to use this
chromatin interaction experiment to explore the unique genetic associations with MS in the
6q23 region to identify possible target causal genes whose expression could be perturbed in at
risk individuals. The ultimate goal is to help translate GWAS findings into clinical benefit, as
the identification of causal genes can pinpoint biological mechanisms altered in disease and
suggest potential therapeutic targets or drug repositioning.
We demonstrate that the MS associated region 6q23 presents numerous, complex chroma-
tin looping interactions clustered in two regions. The first contains SNPs located within the
AHI1 gene, tagged by rs11154801, and correlated with expression, which interact with the
Table 1. MS 6q23 Immunochip associated regions.
Region Co-ordinates (GRCh37) Index SNP Reported Gene MAF P OR
Chr. Start End
6 134946991 135498875 rs11154801 AHI1 0.37 1.80 x 10−20 1.12
6 136685539 136875216 rs17066096 IL22RA2 0.23 1.60 x 10−23 1.14
6 137231416 137660037 rs7769192a - 0.45 3.30 x 10−09 1.08
rs67297943 TNFAIP3 0.22 5.50 x 10−13 1.11
All P values are from the joint analysis by Beecham et al.[6]. Chr., chromosome; MAF, minor allele frequency; OR, odds ratio.
a, P values and ORs shown after conditioning on rs67297943.
doi:10.1371/journal.pone.0166923.t001
Fig 1. Overview of MS 6q23 Immunochip associated regions. Tracks are labelled as follows: A–HindIII restriction fragments; B–LD regions
targeted in ‘region’ Capture Hi-C; C–HindIII restriction fragments targeted in ‘region’ Capture Hi-C; D–Gene regions targeted in ‘promoter’ Capture
Hi-C; E–HindIII restriction fragments targeted in ‘promoter’ Capture Hi-C; F–RefSeq genes (packed for clarity); G–MS index SNPs; H–Density of
MS LD SNPs (r2 0.8) and I–MS LD regions. The genomic region chr6:136,238,000–137,360,000 has been omitted for clarity. All co-ordinates are
based on GRCh37. Generated using the WashU EpiGenome Browser (http://epigenomegateway.wustl.edu/browser/).
doi:10.1371/journal.pone.0166923.g001
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AHI1 promoter thereby supporting the gene candidature of AHI1. Interestingly, these SNPs
also interact with other potential candidate genes such as SGK1 and BCLAF1, suggesting they
may regulate multiple loci. The second region encompasses the rs17066096, rs7769192 and
rs67297943 associated regions and interact with each other and with immune-related genes,
such as IL20RA, IL22RA2, IFNGR1 and TNFAIP3. Additionally, these regions interact with
each other and therefore, may co-regulate these target genes.
Materials and Methods
MS SNP Associations & Regions
All MS SNP associations in the 6q23 region were taken from the IMSGC Immunochip study
[6]. All SNPs in linkage disequilibrium (LD) (r20.8) with each lead Immunochip MS SNP
were identified using European samples from the 1000 Genomes Phase 3 release. Associated
regions for each lead association were defined by the two terminal SNPs in LD.
Cell culture
B-lymphoblastoid cell lines (LCL) were obtained directly from Coriell Institute for Medical
Research (catalogue number GM12878). Cells were grown in vented 25cm2 cell culture flasks
containing 10-20mls of Roswell Park Memorial Institute (RPMI)-1640 + 2mM L-glutamine
culture medium, supplemented with 15% foetal bovine serum (FBS). Flasks were incubated
upright at 37˚C/5% CO2. Cultures were regularly monitored to maintain a cell density between
2×105–5×105 viable cells/ml. Cells were split every 2 days into fresh medium until they reached
a maximum density of 1×106 cells/ml.
Jurkat E6.1 human leukaemic T-lymphoblast cells were obtained directly from LGC Stan-
dards (catalogue number ATCC1 TIB-152™). Cells were grown in vented 25cm2 cell culture
flasks containing 10-20mls of RPMI-1640 + 2mM L-glutamine, supplemented with 10% FBS.
Flasks were incubated upright at 37˚C/5% CO2 and the cultures regularly monitored to main-
tain a cell density between 3×105–9×105 viable cells/ml.
These cell lines are not listed in the in the database of commonly misidentified cell lines
maintained by ICLAC, were authenticated using STR analysis and were tested for mycoplasma
contamination (MycoSEQ1 Mycoplasma Detection System, 4460625, Life Technologies).
Capture Hi-C
Capture Hi-C data was produced as part of a larger study targeting all regions associated with
four autoimmune diseases (RA, JIA, PsA and T1D) and separately, all promoters within these
regions [17]. Briefly, all promoters within 1Mb of associated SNPs were selected and RNA baits
were designed to the ends of all fragments within 500bp of the transcription start sites. Separately,
associated regions were defined by SNPs in LD (r20.8) and all restriction fragments not selected
for the promoter capture experiment were targeted. Experiments were performed using human
T-cell (Jurkat) and B-cell (GM12878) lines. Capture Hi-C libraries were sequenced using 75bp
paired-end reads on an Illumina HiSeq 2500. Resulting reads were mapped to restriction frag-
ments and filtered using the Hi-C User Pipeline (HICUP http://www.bioinformatics.babraham.
ac.uk/projects/hicup). Chromatin interactions were analysed using CHiCAGO (Capture Hi-C
Analysis Of Genomic Organisation [18], http://regulatorygenomicsgroup.org/chicago), a publicly
available, open-source, bespoke statistical model for detecting significant interactions in Capture
Hi-C data at a single restriction fragment resolution. Further filtering was carried out using the
BEDTools v2.21.0 pairtobed command to identify significant interactions involving the MS asso-
ciated regions.
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Chromatin interactions identified in the Capture Hi-C data were further validated against
dense Hi-C data generated by Rao et al. [19] in GM12878 cells. No data was available for the
Jurkat T-cell line. Raw contact matrices and normalisation matrices for GM12878 cells at 5kb
resolution were obtained from GEO accession GSE63525. Observed and expected contact
matrices were normalised using the Knight and Ruiz normalisation matrices as described in
the accompanying documentation. Observed/expected (O/E) values were calculated and fur-
ther filtered by O/E5 and normalised read count 5. BEDTOOLS was used to obtain the
overlap of interactions observed in our data and the Rao et al. [19] data.
Expression quantitative trait loci (eQTLs) analysis
Publicly available datasets from Westra, et al. [20], the GEUVADIS analysis (http://www.ebi.
ac.uk/arrayexpress/files/E-GEUV-1/analysis_results/) and Raj et al. [21] were queried directly.
Additional datasets were also queried through HaploReg [22]. Two whole-genome gene
expression datasets were also available in-house: CD4+ and CD8+ T-cells from 21 healthy
individuals of the National Repository of Healthy Volunteers (NRHV), The University of
Manchester. Written informed consent was obtained from all subjects. Ethical approval was
obtained from North West Centre for Research Ethics Committee (REC: 99/8/84). Samples
were all of Caucasian ancestry with a median age of 50.5 years (26–82 years) and comprised of
8 males and 13 females. mRNA was isolated from sorted cell subsets, quality and concentration
assessed using the Agilent Bioanalyzer and Nanodrop, before cDNA/cRNA conversion using
Illumina TotalPrep RNA Amplification Kits. 750ng of cRNA was hybridised to HumanHT-12
v4 Expression BeadChip arrays according to the manufacturer’s protocol before being scanned
on the Illumina iScan system. Raw expression data were exported from Illumina GenomeStu-
dio and analysed using the R Bioconductor package ‘limma’ 81. Briefly, the neqc function was
used for log2 transformation of the data, background correction and quantile normalisation
using control probes. Principal Component Analysis was used to detect batch effects. The
cDNA/cRNA conversion produced the largest batch effect in both cohorts and was corrected
using ComBat (in R Bioconductor package sva) (http://bioconductor.org/packages/release/
bioc/html/sva.html). Genome-wide genotype data was generated using the Illumina Human-
CoreExome BeadChip kit. Genotype data was aligned to the 1000 genomes reference strand,
pre-phased using SHAPEIT2 (v2.r727), before imputation using IMPUTE2 (v2.3.0) with the
1000 genome reference panel Phase 1. Imputed data was hard-called to genotypes using an
INFO score cut-off of 0.8 and posterior probability of 0.9. The effect of the SNPs on gene
expression was analysed using MatrixEQTL (v 2.1.0) (http://www.bios.unc.edu/research/
genomic_software/Matrix_eQTL/) with an additive linear model. Only SNPs within 4Mb of a
gene expression probe were considered to be cis-eQTL.
Bioinformatics Refinement of SNPs
SNPs were annotated using data from HaploReg v4.1 [22] and RegulomeDB v1.1 [23] for each
LD SNP and combined with our Capture Hi-C data. SNPs attaining a RegulomeDB score of
5 and showing evidence of chromatin interactions in either cell type were selected as poten-
tially causal and merit further investigation.
Results and Discussion
Capture Hi-C
Chromatin interactions at the 6q23 locus were analysed as part of a larger study that included
all known risk loci for RA, juvenile idiopathic arthritis (JIA), PsA and T1D. We performed two
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different Capture Hi-C experiments: firstly, the Region Capture targeted the LD regions
(r2>0.8) for all SNPs associated with each disease (Fig 1B); secondly, the Promoter Capture
targeted all known gene promoters overlapping a region 500kb upstream and downstream of
the lead disease associated SNP (Fig 1D). Capture Hi-C libraries were generated for two cell
lines: GM12878, a B-lymphoblastoid cell line, and Jurkat, a CD4+ T-lymphoblastoid cell line.
Our Capture Hi-C experiments revealed that the 6q23 region presents a complex pattern of
chromosomal interactions, highlighting both new and previously implicated genes for disease
risk. Overall, 827 unique interactions involving MS 6q23 associated regions were observed
across both cell lines and both capture experiments (promoter & region) (Fig 2 and S1 Fig).
Each cell line demonstrated similar interaction patterns in both capture experiments. Encour-
agingly, there was a high degree of support from previously published Hi-C data obtained in
GM12878 cells [19], with between 81% and 90% of interactions identified through our Capture
Hi-C also being seen at an observed/expected ratio of5 in previously published data.
The numerous chromosomal interactions detected appeared to cluster in two genomic
locations, involving the rs11154801 region and a region containing the other three indepen-
dent MS associations: rs17066096, rs7769192 and rs67297943 (Fig 2).
The rs11154801 LD block spans 170.4kb and contains several enhancers overlapping SNPs
in strong LD with the lead association. It demonstrates a complex array of several long-range
(>100kb) as well as shorter (<100kb) chromatin interactions (Fig 2 and S2 Fig) in both cell
lines. Shorter internal chromatin interactions include ones with restriction fragments flanking
the AHI1 gene (previously assigned as the candidate gene to this variant) promoter, and SNPs
in LD with rs11154801. We show how these SNPs, within the introns of AHI1, interact with
the promoter region thereby supporting the AHI1 hypothesis in both cell lines. Mutations in
AHI1 have been shown to cause Joubert syndrome [24], an autosomal recessive neurological
condition causing symptoms including neonatal breathing abnormalities and mental retarda-
tion. Furthermore, it has been suggested that AHI1 is required for both cerebellar and cortical
development in humans and is expressed in the brain [25].
However, this locus may be more complex than previously thought, as long-range chroma-
tin interactions, although more numerous in B-cells, were observed between the enhancer
region and other compelling candidates such as SGK1 and BCLAF1 in both cell lines. The
Fig 2. Overview of MS 6q23 interactions. Tracks are labelled as follows: A–LD regions targeted in ‘region’ Capture Hi-C; B–Gene regions
targeted in ‘promoter’ Capture Hi-C; C–RefSeq genes (packed for clarity); D–MS index SNPs; E–MS LD regions; F–Interactions observed in the
GM12878 B-cell line and G–Interactions observed in the Jurkat T-cell line. Promoter and region Capture Hi-C experiments have been merged for
clarity. The genomic region chr6:136,650,000–137,280,000 has been omitted for clarity. All co-ordinates are based on GRCh37. Generated using
the WashU EpiGenome Browser (http://epigenomegateway.wustl.edu/browser/).
doi:10.1371/journal.pone.0166923.g002
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interaction with SGK1 represents a>1.2Mb interaction and Sgk1 knockout mice have been
shown to have a reduced incidence of disease severity in experimental autoimmune encephalo-
myelitis (EAE), a mouse model of MS [26]. Other long-range interactions include those to the
MYC and PDE7B gene regions.
Finally, rs11154801 also showed an interaction in both B and T-cells with a region encom-
passing the promoters of BCLAF1,MTFR2, an antisense gene (RP13-143G15.4) overlapping
PDE7B and a lincRNA (RP3-406A7.7). The BCLAF1 gene encodes a transcriptional repressor
which interacts with BCL2-family proteins, is expressed in the brain and overexpression can
lead to cell apoptosis [27]. In lymphocytes, dysregulation of BCL2-family proteins has been
shown to lead to a reduction of pro-apoptotic BCL-2 members and survival of T-cells in MS
[28]. Additionally, BCLAF1 has also been shown to be crucial in the homeostasis of T- and B-
cell lineages and proliferation of T-cells [29]. These interactions suggest that the associations at
this locus may have different or additional effects on disease than just the previously assigned
AHI1 gene.
The second cluster of chromatin interactions involve the remaining MS associated SNPs in
the 6q23 region, rs17066096, rs7769192 and rs67297943. Our Capture Hi-C results showed
that these three SNPs interact with each other and also with several genes with immune func-
tion such as IL20RA, IL22RA2, IFNGR1 and TNFAIP3, suggesting that these variants may be
involved in the regulation of common immune pathways (Fig 2).
The first two interacting regions in this cluster, identified by the promoter Capture Hi-C
experiment and tagged by rs17066096, were only observed in B-cells and involved the
IL22RA2 and IFNGR1 gene promoters, almost 71kb and 113kb away, respectively. The restric-
tion fragment overlapping the rs17066096 LD block shows evidence of enhancer activity, as
predicted by ChromHMM, and the furthest 5’ SNP in LD with the index SNP is located within
this enhancer.
The region tagged by rs7769192 spans 50kb and contains 72 SNPs in LD, 21 of which are
perfectly correlated with the lead SNP. It shows evidence of multiple enhancers and in addition
to the previously mentioned interaction with the rs17066096 region, interacts with five other
regions, in both cell lines. The first of these is located>500kb 5’ of rs7769192 and contains the
IL20RA gene. The next two regions, located over 400kb away, are shared with the rs17066096
region and contain the IL22RA2 and IFNGR1 genes, providing further evidence of the inter-
play between the two associated regions. The product of the IFNGR1 gene is a subunit of the
interferon gamma (IFN-γ) receptor whose ligand, IFN-γ, is important in adaptive immunity
and has been linked to many different autoimmune diseases [30]. The IL20RA and IL22RA2
genes both encode receptors for members of the IL-20 sub-family of cytokines and both
exhibit a pro-inflammatory effect [31]. Additionally, anti-IL20 therapy has recently been
shown to be effective in the treatment of RA and psoriasis [32,33]. Although anti-IL20 therapy
was not developed as a result of Capture Hi-C, the discovery of interactions between these
genes and autoimmune disease associations, demonstrates the power of this technique to
inform drug discovery or repositioning. Further evidence for anti-IL20 therapy comes from
the interaction with IL22RA2. IL22RA2 encodes a soluble receptor which binds to and inhibits
IL-22, a cytokine which can stimulate pro-inflammatory epithelial defence mechanisms [34],
preventing the interaction with its cell surface receptor. This evidence suggests that blocking
the IL-20 pathway may be effective in the treatment of MS and other autoimmune diseases.
The fourth region is located 178kb 3’ of the associated region and contains multiple pro-
moters of the TNFAIP3 gene as well as a non-coding processed transcript (RP11-356I2.4) of
unknown function. The role of TNFAIP3 in autoimmunity is well established and the gene
product A20 is a protein that is induced by tumour necrosis factor (TNF) and inhibits NFκB
activation and TNF-mediated apoptosis [35]. This locus within the 6q23 region is one of the
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most important autoimmunity risk loci, as it contains multiple SNPs strongly associated with
many autoimmune diseases, including MS, RA, SLE, CeD, IBD, psoriasis and PsA, among oth-
ers. Variants associated with most autoimmune diseases map to the TNFAIP3 gene or its vicin-
ity, including the MS SNPs rs17066096, rs7769192 and rs67297943.
The rs67297943 SNP is located within a predicted enhancer element in B-cells and also in a
48.8kb region showing multiple enhancer marks in both B and T-cells. Furthermore, the adja-
cent restriction fragment to rs67297943 interacts with the IL20RA promoter region only in B-
cells in this experiment.
Our Capture Hi-C results suggest that rs17066096, rs7769192 and rs67297943 physically
interact with several immune genes with pro-inflammatory roles, such as IL20RA, IL22RA2,
IFNGR1 and TNFAIP3, indicating that they may be involved in the inflammatory processes
that typically occurs in autoimmunity. Conversely, rs11154801, which is exclusively associated
to MS and not other autoimmune diseases, interacts with genes with neurological function,
like AHI1, SGK1 and BCLAF1. Intriguingly, these two separate regions, over 2.3Mb apart,
interact with each other in T-cells but not B-cells (S1 Fig), suggesting that these pathways may
converge to give rise to disease-specific MS mechanisms in a stimulus and cell type specific
manner. In this regard, it has been previously shown that there is a correlation between chro-
matin interactions and gene co-expression [36–39] and it has been hypothesised that multiple
co-regulated genes can interact and share regulatory elements at specialised ‘transcription fac-
tories‘ [16]. Our data possibly supports this idea and suggests a possible co-regulation of genes
in this region in MS.
It could be argued that the differences observed between cell types for the rs1154801 region
and the rs17066096 region could also be attributable to genotype differences in the cell lines
(Table 2). While the overall pattern of chromatin interactions is similar for the rs11154801,
rs17066096 and MYB regions, the intensity of interactions observed does vary between cell
lines and could be due to carriage of risk alleles in the B-cell line, absent in the T-cell line. It is
therefore important to validate the chromatin interactions in a genotype specific manner.
Expression Quantitative Trait Loci (eQTLs)
Public databases were interrogated for evidence of eQTLs for MS associated SNPs in the 6q23
region (rs11154801, rs17066096, rs7769192 and rs67297943) and all SNPs in LD (r2>0.8) with
them. The SNPs within the intergenic region 5’ of the AHI1 gene, tagged by rs11154801 and
interacting with the AHI1 gene promoter, are correlated with AHI1 mRNA expression in mul-
tiple tissues, including brain, nerve and whole blood. This further supports that AHI1 is one of
the causal genes within the 6q23 region.
Although many of the interactions detected in the Capture Hi-C experiment are between
regions which show enhancer activity and regions which show active transcription, no eQTL
evidence from public databases was observed for any of the other MS associated SNPs
Table 2. Associated SNP genotypes for GM12878 (B) and Jurkat (T) cell lines.
SNP Risk Allele GM12878 Jurkat
Genotype Number of risk alleles Genotype Number of risk alleles
rs11154801 A CA 1 CC 0
rs17066096 G AA 0 AG 1
rs7769192 A AA 2 unknown*
rs67297943 C TC 1 unknown*
*Neither directly genotyped nor suitable proxies available on array
doi:10.1371/journal.pone.0166923.t002
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investigated, other than rs11154801. This could be due to the distance cut-offs used to define
cis effects or the selection of the correct cell type and stimulatory conditions, as eQTLs are
known to be highly cell type and stimulus specific.
However, using in-house eQTL data on CD4+ and CD8+ primary T-cells from healthy
donors, rs17066096 was shown to be correlated with expression of IL20RA in CD8+ T-cells
(P = 0.01, Fig 3). Although the design of the Capture Hi-C experiment did not allow for the
testing of chromatin interactions between the rs17066096 region and IL20RA, this eQTL sug-
gests IL20RA could be important in the pathogenesis of MS in CD8+ T-cells, which have previ-
ously been shown to contribute to disease [40]. This data also confirmed the eQTL between
rs11154801 and AHI1 in both CD4+ and CD8+ T-cells (P = 2.0x10-4 and 0.02 respectively).
Full eQTL results for all MS SNPs are presented in S2 Data. No other eQTLs were identified
between MS SNPs and genes showing chromatin interactions, this may again be due to the
selection of the correct cell type and stimulatory conditions.
Bioinformatics Refinement of SNPs
By utilising publically available data on regulatory elements obtained through HaploReg and
RegulomeDB and augmenting with our Capture Hi-C data, we were able to refine large num-
bers of potential causal SNPs for three out of the four MS associated regions, by strong evi-
dence of being in both a relevant cell-type enhancer region and interacting with a gene
promoter (Table 3 and S3 Data). For the rs11154801 region, 6 SNPs were identified out of 19
potential candidates; for the rs17066096, 3 SNPs were selected from a total of 7 in LD with the
index association; and finally, for the rs7769192 region, we refined the potential candidates to
4 SNPs out of 72 in LD with rs7769192. No SNPs were found in LD with rs67297943 and
although this SNP shows enhancer marks in 6 tissues, no interactions were identified with this
region and as such further refinement was not possible. It will be imperative to follow-up puta-
tive SNPs and genes with functional assays and demonstrate their contribution to disease in
relevant cell types in a biological context using genome editing techniques.
Conclusion
In conclusion, our work has strengthened the case for the AHI1 gene candidate but also identi-
fied other potential MS gene targets, such as SGK1, BCLAF1 IL20RA, IL22RA2, IFNGR1 and
TNFAIP3. Additionally, we have shown a possible co-regulation of MS GWAS associations in
the 6q23 region, which could help elucidate the pathogenesis of MS as well as other autoim-
mune diseases. These targets require further functional investigation which has been informed
by the bioinformatics analysis. While the MS associations show evidence of interacting with
other genes with no obvious role in MS pathogenesis, it is likely that they share regulatory ele-
ments within this region. It is however important to investigate these interactions, in addition
to ones highlighted in this analysis to fully explore disease pathogenesis.
Whilst the interactions identified require further independent validation, the unique exper-
imental design using complementary capture baits (region and promoter captures) provides
robust evidence of chromatin interactions. Additionally, validation with chromatin interac-
tions identified by Rao et al. [19] further add to the confidence of the observed interactions.
While Capture Hi-C offers much greater resolution for chromatin interactions than Hi-C,
observed interactions are still limited by the restriction enzyme used and do not pinpoint the
interactions to specific enhancers. As such further work will be necessary to confirm causal
enhancers and how they affect gene regulation. The use of cell lines is a limitation of the study
but the experimental requirement of high cell numbers for Capture Hi-C makes the use of pri-
mary cells challenging. However, it is essential that further experiments are performed in
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primary cells to fully elucidate how chromatin interactions can effect gene regulation in MS.
Despite these limitations of Capture Hi-C, it is clear that this technique is a powerful approach
to link genes to their regulatory elements and this work has identified several candidate causal
genes for MS. Additionally it has been proposed that by using genetic evidence to select drug
targets, it could double the success rate in clinical development [41]. Since Capture Hi-C has
Fig 3. Increased expression of IL20RA in primary CD8+ T-cells from 21 healthy individuals carrying the G risk allele of rs17066096,
P = 0.01. The three different genotypes for the SNPs are displayed on the X axis and gene expression levels on the Y axis. Error bars indicate
standard deviation.
doi:10.1371/journal.pone.0166923.g003
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the potential to identify causal genes for genetic associations, it provides a way to enhance this
further. This is exemplified by the identification of chromatin interactions between MS associ-
ations and the IL20RA and IL22RA2 genes, showing a potential use of anti-IL20 therapy in MS,
and highlights the potential of Capture Hi-C to provide novel therapeutic targets or drug repo-
sitioning to improve patient outcome.
Supporting Information
S1 Data. LD between MS associated SNPs and other disease associated SNPs in the 6q23
region. Disease abbreviations are as follows: CEL–Coeliac disease; CRO–Crohn’s disease; MS–
Multiple sclerosis; PBC–Primary biliary cirrhosis; PSO–Psoriasis; RA–Rheumatoid arthritis;
SLE–Systemic lupus erythematosus; T1D –Type 1 diabetes; UC–Ulcerative colitis; SJO—Sjog-
ren Syndrome.
(XLSX)
S2 Data. NRHV CD4 and CD8 eQTLs for MS SNPs within the 6q23 region.
(XLSX)
S3 Data. Full table of bioinformatics and Capture Hi-C data analysis. Refined SNPs are
highlighted in green.
(XLSX)
S1 Fig. Interactions within the rs11154801 LD region. Tracks are labelled as follows: A–LD
regions targeted in ‘region’ Capture Hi-C; B–Gene regions targeted in ‘promoter’ Capture Hi-
C; C–GENCODE Genes V17; D–MS index SNPs; E–MS LD regions; F–Interactions observed
in the GM12878 B-cell line and G–Interactions observed in the Jurkat T-cell line. All co-ordi-
nates are based on GRCh37.
(TIF)
S2 Fig. Full overview of MS 6q23 Immunochip associated regions. Tracks are labelled as fol-
lows: A–LD regions targeted in ‘region’ Capture Hi-C; B–Gene regions targeted in ‘promoter’
Capture Hi-C; C–RefSeq genes (packed for clarity); D–MS index SNPs; E–MS LD regions; F–
Interactions observed in the GM12878 B-cell line and G–Interactions observed in the Jurkat
T-cell line. All co-ordinates are based on GRCh37.
(TIF)
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